Asset Transaction Form 8 K

Item 2.01. Completion of Acquisition or Disposition of Assets.

On December 2, 2024, Nektar Therapeutics, a Delaware corporation ("Nektar"), completed its previously announced disposition to an affiliate of Ampersand Management LLC d/b/a Ampersand Capital Partners, a Delaware limited liability company (said affiliate, "Purchaser"), of Nektar's manufacturing facility located in Huntsville, Alabama and certain other manufacturing assets related thereto, as well as Purchaser's assumption of certain related liabilities (collectively, the "Transactions").

The foregoing description of the Transactions does not purport to be complete, and is qualified in its entirety by reference to the full text of the Asset Purchase Agreement, dated as of November 1, 2024, entered into between Nektar and Purchaser, which was filed as Exhibit 1.1 to Nektar's Current Report on Form 8-K filed on November 4, 2024, and is hereby incorporated herein by reference.